Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05340868
NA

Genetics of the Acute Response to Oral Semaglutide

Sponsor: Medical University of Bialystok

View on ClinicalTrials.gov

Summary

The study aims to investigate the genetic basis of the response to short-term (3 months) orally administered semaglutide treatment, in terms of improving metabolic parameters, including the hormonal response to a standardized meal, and changes in body composition and liver steatosis. In the study, parameters such as fasting and 2-hour glucose during OGTT, HbA1c, body fat mass, body weight, total cholesterol, HDL and LDL, triglycerides, HOMA-IR, Matsuda Index and liver steatosis will be assessed. All the patients will undergo genome-wide genotyping. Moreover, in a subset of participants, muscle and fat biopsies will be performed, before and after the treatment, and liver, muscle and pancreas fat content will be assessed using MRI.

Official title: Genetics of the Acute Response to Oral Semaglutide (GAROS)

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

1000

Start Date

2022-09-01

Completion Date

2025-12-31

Last Updated

2025-03-26

Healthy Volunteers

Yes

Interventions

DRUG

Semaglutide Pill

Oral semaglutide treatment

Locations (1)

Clinical Research Centre, Medical University of Bialystok

Bialystok, Podlaskie Voivodeship, Poland